<SEC-DOCUMENT>0001628280-25-049865.txt : 20251106
<SEC-HEADER>0001628280-25-049865.hdr.sgml : 20251106
<ACCEPTANCE-DATETIME>20251106073049
ACCESSION NUMBER:		0001628280-25-049865
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251106
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251106
DATE AS OF CHANGE:		20251106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRESCENT BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		251456162

	BUSINESS ADDRESS:	
		STREET 1:		300 FIFTH AVENUE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-430-5595

	MAIL ADDRESS:	
		STREET 1:		300 FIFTH AVENUE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLYCOMIMETICS INC
		DATE OF NAME CHANGE:	20030711
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cbio-20251106.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:77c2f864-6fb7-459c-9e5f-aaeb1b69cd1d,g:b89f3300-40b4-4232-ba44-be05274246a8,d:5ab61d66f4be4b26a0d1804e5505467e-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cbio-20251106</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001253689</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cbio-20251106.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-06</xbrli:startDate><xbrli:endDate>2025-11-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5ab61d66f4be4b26a0d1804e5505467e_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 6, 2025</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Crescent Biopharma, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Charter)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________________________</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-4">Cayman Islands</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36177</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">06-1686563</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">300 Fifth Avenue</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Waltham</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">02451</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">617</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">430-5595</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________________________</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2. below):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.416%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Trading symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Ordinary Shares, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">CBIO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">o</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div></div><div id="i5ab61d66f4be4b26a0d1804e5505467e_4"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2025, Crescent Biopharma, Inc. (the &#8220;Company&#8221;) issued a press release announcing the Company&#8217;s financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02 and Exhibits 99.1 attached hereto is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.</span></div><div id="i5ab61d66f4be4b26a0d1804e5505467e_7"></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="pressrelease-q32025.htm">Press Release issued by Crescent Biopharma, Inc. on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="pressrelease-q32025.htm">November</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="pressrelease-q32025.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="pressrelease-q32025.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="pressrelease-q32025.htm">, 2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div></div><div id="i5ab61d66f4be4b26a0d1804e5505467e_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:24pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">CRESCENT BIOPHARMA, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date: November 6, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Joshua Brumm</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Name:</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Joshua Brumm</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Title:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressrelease-q32025.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i4ad4e64e0c104a00930d54733483c695_1"></div><div style="min-height:87.66pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:168px"></div></div><div style="margin-bottom:8pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Crescent Biopharma Reports Third Quarter 2025 Financial Results <br>and Recent Business Highlights</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Advancing ADCs in the Pipeline, with IND Submission for CR-002 on Track for Mid-2026</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:115%">Waltham, Mass., November 6, 2025 &#8211; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">Crescent Biopharma, Inc. (&#8220;Crescent&#8221; or the &#8220;Company&#8221;) (Nasdaq&#58; CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the third quarter ended September 30, 2025, and recent business highlights.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">&#8220;We have made exciting progress during 2025 advancing our pipeline of next generation therapeutics for solid tumors toward the clinic,&#8221; said Joshua Brumm, chief executive officer of Crescent. &#8220;For CR-001, our PD-1 x VEGF bispecific antibody, we are presenting preclinical data at SITC demonstrating cooperative pharmacology and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:112%">in vivo </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">anti-tumor activity. We are thrilled with the engagement from clinicians who share our enthusiasm for CR-001 and plan to commence our global Phase 1 trial in patients with solid tumors in the first quarter of 2026 with initial data anticipated later next year. In addition, we continue to progress our ADC programs and expect to submit an IND for CR-002 in mid-2026. We remain focused on executing across the business with the goal of delivering the next wave of transformative therapies for people living with cancer.&#8221; </font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Recent Business Highlights &#38; Upcoming Milestones</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">CR-001, a PD-1 x VEGF bispecific antibody</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%;padding-left:13.8pt">CR-001 is a tetravalent bispecific antibody being developed for the treatment of solid tumors that combines two complementary, validated mechanisms in oncology via a blockade of PD-1 and VEGF. It was designed to replicate the cooperative pharmacology of ivonescimab, which demonstrated superior efficacy compared to the current market leader, pembrolizumab, in a large, third-party Phase 3 trial in non-small cell lung cancer.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:110%;position:relative;top:-3.48pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%"> </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%;padding-left:14.33pt">Preclinical data from CR-001 will be featured in a poster presentation on November 7, 2025, at the Society for Immunotherapy of Cancer&#8217;s (SITC) 40th Annual Meeting in National Harbor, Maryland. CR-001 demonstrated cooperative pharmacology with increased binding to PD-1 in the presence of VEGF, augmenting the PD-1&#47;PD-L1 signaling blockade and enhancing T-cell activation in vitro. This cooperativity was consistent with preclinical evaluation of ivonescimab.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.82pt;font-weight:400;line-height:110%;position:relative;top:-3.67pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%"> CR-001 also showed potent anti-tumor activity in a xenograft mouse model and was well-tolerated in non-human primates after a single intravenous dose with robust PD-1 receptor occupancy. The poster will be available on the day of the presentation in the Presentations &#38; Publications section of Crescent&#8217;s website. </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%;padding-left:14.33pt">Crescent remains on track to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for CR-001 in the fourth quarter of 2025 and expects to report proof-of-concept clinical data from a global Phase 1 trial in patients with solid tumors in the second half of 2026.<br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.66pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:168px"></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">CR-002 and CR-003, novel antibody-drug conjugates (ADCs)</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:13pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%;padding-left:13.45pt">CR-002 and CR-003 are novel ADCs with topoisomerase inhibitor payloads that are being developed as single agents and in combination with CR-001. Crescent expects to submit an IND application for CR-002 in mid-2026.<br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Third Quarter 2025 Financial Results</font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Cash position&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;Cash was </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">$133.3 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> as of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">September&#160;30, 2025</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">, which is anticipated to fund operations through 2027. </font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Research and development (R&#38;D) expenses&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;R&#38;D expenses were </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">$20.3 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> for the three months ended </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">September&#160;30, 2025</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">General and administrative (G&#38;A) expenses&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;G&#38;A expenses were </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">$5.5 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> for the three months ended </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">September&#160;30, 2025</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Net loss&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;Net loss was </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">$24.6 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">, or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">$1.27</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> per basic and diluted share, for the three months ended </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">September&#160;30, 2025</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Shares outstanding&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;As of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">September&#160;30, 2025</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">, Crescent had approximately </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">19.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> million shares of the Company&#8217;s ordinary shares and ordinary share equivalents issued and outstanding, including ordinary shares underlying pre-funded warrants and non-voting convertible preferred stock.</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">About Crescent Biopharma</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Crescent Biopharma&#8217;s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company&#8217;s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit&#160;www.crescentbiopharma.com&#160;and follow the Company on&#160;LinkedIn&#160;and&#160;X.<br><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Certain statements in this press release, other than purely historical information, may constitute &#34;forward-looking statements&#34; within the meaning of the federal securities laws, including for purposes of the &#34;safe harbor&#34; provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Crescent&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, the expected benefits or opportunities with respect to CR-001, CR-002 and CR-003, including the expected timelines of regulatory filings, initial clinical data for CR-001 and CR-002, the potential for CR-001 to replicate the cooperative pharmacology of ivonescimab in clinical trials, the potential for CR-001 to replicate preclinical demonstration of cooperative pharmacology and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:112%">in vivo</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%"> anti-tumor activity in clinical trials, the proposed Phase 1 trial design for CR-001, the potential for CR-002 and CR-003 to act as single agents and in combination with CR-001, and Crescent&#8217;s anticipated cash runway. The words &#34;opportunity,&#34; &#34;potential,&#34; &#34;milestones,&#34; &#34;pipeline,&#34; &#34;can,&#34; &#34;goal,&#34; &#34;strategy,&#34; &#34;target,&#34; &#34;anticipate,&#34; &#34;achieve,&#34; &#34;believe,&#34; &#34;contemplate,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intends,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;possible,&#34; &#34;project,&#34; &#34;should,&#34; &#34;will,&#34; &#34;would&#34; and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.66pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:168px"></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">assurance that future developments affecting Crescent will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Crescent&#8217;s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, Crescent&#8217;s limited operating history, including with respect to clinical trials, Crescent&#8217;s historical losses and any future ability to generate revenue, Crescent&#8217;s ability to raise capital to support its business plans, risks associated with clinical development and regulatory approval, risks related to Crescent&#8217;s intellectual property, Crescent&#8217;s reliance on third parties, including to help develop its product candidates and run its clinical trials, as well as to manufacture its product candidates, Crescent&#8217;s dependence on key personnel, Crescent&#8217;s estimates of market opportunity may prove to be inaccurate, significant disruptions of information technology systems or breaches of data security, litigation and regulatory risks, as well as those factors more fully described in Crescent&#8217;s most recent filings with the Securities and Exchange Commission (including its Quarterly Report on Form 10-Q), and Crescent&#8217;s other filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Crescent&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Crescent does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Crescent.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.66pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:168px"></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:133%">Crescent Biopharma, Inc.<br>Condensed Consolidated Statement of Operations<br>(in thousands, except share and per share data)<br>(Unaudited)</font></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.910%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">Three Months Ended September 30, 2025</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">Nine Months Ended September 30, 2025</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">Period from September 19, 2024 (Inception) Through September 30, 2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Operating expenses</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">20,347&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">43,059&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">2,473&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">5,538&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">18,081&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">158&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">25,885&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">61,140&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">2,631&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(25,885)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(61,140)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(2,631)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Other income (expense)</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">1,278&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(405)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Net loss and comprehensive loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(24,607)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(61,545)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(2,631)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Net loss per share attributable to ordinary shareholders, basic and diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(1.27)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(7.89)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(3.60)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Net loss per share attributable to Series A non-voting convertible preferred shareholders, basic and diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(1,266.44)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(7,891.38)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Weighted-average ordinary shares outstanding used in computing net loss per share to ordinary shareholders, basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">16,540,771</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">6,640,402</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">730,092</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Weighted-average Series A non-voting convertible preferred shares outstanding used in computing net loss per share to Series A non-voting convertible preferred shareholders, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">2,890</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">1,160</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">&#8212;</font></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%"><br>Summary Balance Sheet Data<br>(in thousands)<br>(Unaudited)</font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">September 30, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">December 31, 2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Cash</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">133,265&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">34,766&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Other assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">5,004&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">851&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Total Assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">138,269&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">35,617&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">Liabilities and Shareholders' Equity (Deficit)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Liabilities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">21,628&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">47,096&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Shareholders' equity (deficit) and convertible preferred shares</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">116,641&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(11,479)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Total liabilities and shareholders' equity (deficit)</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">138,269&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">35,617&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.66pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:168px"></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:134%">References&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">1.    Xiong A, et al. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:115%">Lancet</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">. 2025&#59; 405(10481)&#58;839-849.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">2.    Zhong T, et al. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:115%">iScience</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">. 2024&#59; 28(3)&#58;111722.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Contact&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:133%">Amy Reilly</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:133%">Chief Communications Officer</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:133%">amy.reilly&#64;crescentbiopharma.com </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:133%">617-465-0586</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cbio-20251106.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:77c2f864-6fb7-459c-9e5f-aaeb1b69cd1d,g:b89f3300-40b4-4232-ba44-be05274246a8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cbio="http://crescentbiopharma.com/20251106" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://crescentbiopharma.com/20251106">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20251106_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20251106_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://crescentbiopharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cbio-20251106_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:77c2f864-6fb7-459c-9e5f-aaeb1b69cd1d,g:b89f3300-40b4-4232-ba44-be05274246a8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_7a0d9354-8e50-4b2b-a3a9-950b7c83fef9_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_a85e961f-d73f-4ce1-96ea-19c203282f28_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9dd9ae65-1a08-4454-ade7-c2e3d3ba3953_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c4e57619-a8df-43fc-8f5e-861c0f1e8a2a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_54dd3fc0-c46c-4793-a6c6-5e70fffd0612_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_53a64d5d-1422-4afe-8877-ded1441571ce_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5f03ab46-8571-49eb-a4ee-a5140d559fa1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2db9901a-a2c3-4769-b399-df483eda16cc_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_1564be0e-bc8b-4d69-8b96-983bd3fc014b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_af96815e-3fad-4141-8df8-359920190230_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b2fd802e-263a-456e-9ee1-19dda3e59c2d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0a246a11-945a-4025-9f9a-deb56d0a63c4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b85cee90-a1a4-4a02-bf26-2f20a1dec0fd_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1d543b09-9136-438d-a581-e1ae570c57de_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_48727579-78ca-41cf-988b-9d4a5acf8239_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f34ccf57-b9b2-4cb6-809a-bd624631cc24_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2ac40e52-0cbf-4bf4-a3bb-6154a0a4fb66_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9524d0bf-491f-4730-a390-98be5d1cd6a3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1bded25d-45fb-4066-a618-71cf23798573_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_33e61077-bb05-4bef-923d-a1846c4f3c5e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_55f829ab-b15e-413e-a40b-47e562fc6faa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4df42551-21ef-4721-bc72-f5d00389470f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_984352bd-f0df-47ea-b88a-09e73303abd2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cbio-20251106_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:77c2f864-6fb7-459c-9e5f-aaeb1b69cd1d,g:b89f3300-40b4-4232-ba44-be05274246a8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://crescentbiopharma.com/role/Cover" xlink:type="simple" xlink:href="cbio-20251106.xsd#Cover"/>
  <link:presentationLink xlink:role="http://crescentbiopharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a78dee6a-0cb2-4bcd-8062-3e01631653a3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_DocumentType_a78dee6a-0cb2-4bcd-8062-3e01631653a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f8b92198-1242-43d7-aa16-acbe4cdb0bae" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_DocumentPeriodEndDate_f8b92198-1242-43d7-aa16-acbe4cdb0bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a6c5bc7e-a6ee-459c-a27b-65be5d745f0a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityRegistrantName_a6c5bc7e-a6ee-459c-a27b-65be5d745f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_22924b49-2649-4e9d-a825-2d62d89b5fd8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityIncorporationStateCountryCode_22924b49-2649-4e9d-a825-2d62d89b5fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5836882b-0be5-4fec-95d3-1126e4e5ed67" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityFileNumber_5836882b-0be5-4fec-95d3-1126e4e5ed67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ad50c8a0-16ba-48ae-a98c-5689559b9f2a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityTaxIdentificationNumber_ad50c8a0-16ba-48ae-a98c-5689559b9f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9165a536-cd94-4900-895a-7068580ef618" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityAddressAddressLine1_9165a536-cd94-4900-895a-7068580ef618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_efdac4aa-2800-4f41-bc55-4ef77b21b91d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityAddressCityOrTown_efdac4aa-2800-4f41-bc55-4ef77b21b91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_fd142b1c-a8ff-4d7f-8e38-bab0acd5f6ac" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityAddressStateOrProvince_fd142b1c-a8ff-4d7f-8e38-bab0acd5f6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2b76b77e-ae66-4723-94e9-cb81e29b575e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityAddressPostalZipCode_2b76b77e-ae66-4723-94e9-cb81e29b575e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d38bbe42-db94-47dc-9ae7-629ddd194c51" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_CityAreaCode_d38bbe42-db94-47dc-9ae7-629ddd194c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f4e47c66-cad4-4911-94b5-38b158f787d2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_LocalPhoneNumber_f4e47c66-cad4-4911-94b5-38b158f787d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_7eb11177-f28a-4ab8-80f7-bfd57ecb654b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_WrittenCommunications_7eb11177-f28a-4ab8-80f7-bfd57ecb654b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a744bb2a-1913-46cd-86bd-a545aa98bed0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_SolicitingMaterial_a744bb2a-1913-46cd-86bd-a545aa98bed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_94b98ba9-8dd3-46fe-9e1a-94a4f0789704" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_PreCommencementTenderOffer_94b98ba9-8dd3-46fe-9e1a-94a4f0789704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_95af1828-8294-419e-bba8-0305c61ee66b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_95af1828-8294-419e-bba8-0305c61ee66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cdc129bc-5e11-4ebe-8819-dc78f98aa9a4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_Security12bTitle_cdc129bc-5e11-4ebe-8819-dc78f98aa9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5cb4013d-f942-40c5-b4a5-b2860c495381" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_TradingSymbol_5cb4013d-f942-40c5-b4a5-b2860c495381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8c36026f-55af-49d3-9c47-24614e7f545f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_SecurityExchangeName_8c36026f-55af-49d3-9c47-24614e7f545f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b6936b3a-b8d4-4baa-b362-9a421d5a4b7e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityEmergingGrowthCompany_b6936b3a-b8d4-4baa-b362-9a421d5a4b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_33ad07f8-064c-4f66-b0d6-230c6a8d4df6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityCentralIndexKey_33ad07f8-064c-4f66-b0d6-230c6a8d4df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_809986df-41d9-4f4a-8faf-1d8c5723ecf2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_AmendmentFlag_809986df-41d9-4f4a-8faf-1d8c5723ecf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" $U UT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M JS A@0>N/$GEF80P2QDJ4E2;MS6TOV_3UT/<AFN6U,>\%&K%U4N;EOK;O\
MKZ:['J5%%%<)Z 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\6>.O@M\-K?1-4\;:@+SQ'=17,LGVB3<[X42.PB3=([;$"KECQTQ\??M9?\
M! 3P)^TI^U'J?Q^T?X\WGAW3/$FHB^\2:$-$6XD:<X\UK>8RJ(_,()PR-M9B
M?F&%'NY-Q=AY\05,5CL544/9\L6XQO?1M-1BUOS.+MVN^A\WGO!N*CPY2PF
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*** "BBB@ HZT44 5;'0]%TR*:#3=(M;>.X<O.D%NJ"1CU+ #DGU-?G]8_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGI!)\W("-(<X_0JOCL5A,1@JOLZT;/\ K;N=T)QJ*\6%%%%<Q84444 %%%%
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MN4@@@&O2?VZO''B7X9_L5_%KXA>#-2>RU?1?AOK5[IEY&<-;W$=E*T<B^ZL
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M^V1_P4-UC/P-^'OV;PY!/Y6H>-=?9K;2[8C[RB3:6G<=XXE=AD;@H.:^H?\
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M/W(HU. .I.6.69B?7R+)O[2JNI4_AQW\WV_S,,37]DK+=G0?MM_\%!?VH/\
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MOWD8&YBZ[F3U<NXEPN-J*G47))[=4_G_ )F-7"3IJZU1\M_\$V?^"NG[3_\
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M1W<0$HP>=I)0X^92.*_!'_@KE_P0W^+G_!.BYE^+?PZU*[\8_"BYNA''KC0
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M"J\R(W0L ?SK^S3P'#%;>!M%MX$"QQZ3;*BCH (E %=G&$VJ5&/=M_=;_,C
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M/AW<*S>?;W#8]PML/PK]I*_.<YPT<)F=2G':]U\]?U/4H3YZ29_-=_P<N_\
M*5KQ/_V*VB_^DBU\"5]]_P#!R[_RE:\3_P#8K:+_ .DBU\"5^DY3_P BRC_A
M7Y'E5_XTO4_7W_@U?_82T+Q]XZ\3_MV?$+1$NH?"-U_8?@A9X]R+J+Q![JY
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MFFI_,1_P<,^)+CQ'_P %;_BB)I"4L%TBSA7LJII5ID#_ ($6/XU\55]E?\'
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MT:/=?^%3I/\ \E5U85Y%@Y.5&<(M_P!Y?YD3^LU%:2;^1\;5_83^R-=W-_\
MLH_#&^O PFG^'FBR2ACD[C8PDY_$U_-^/^#?W_@K@3C_ (9'NOK_ ,)3I/\
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M^#;G_@FS\?9+C6?!'@W5OAIJ\V6%SX+O]MH7/]ZTG$D2K_LQ"/ZU\$?M _\
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MOHK'BQYE)<NY^BG_ !%I?MD_]&U_#+\M1_\ DFC_ (BTOVR?^C:_AE^6H_\
MR37S?_Q#_?\ !7#_ *-'NO\ PJ=)_P#DJC_B'^_X*X?]&CW7_A4Z3_\ )5>%
M]4X8_N?^!+_,Z.?&>?W'TA_Q%I?MD_\ 1M?PR_+4?_DFC_B+2_;)_P"C:_AE
M^6H__)-?-_\ Q#_?\%</^C1[K_PJ=)_^2J/^(?[_ (*X?]&CW7_A4Z3_ /)5
M'U3AC^Y_X$O\PY\9Y_<?2'_$6E^V3_T;7\,ORU'_ .2:/^(M+]LG_HVOX9?E
MJ/\ \DU\W_\ $/\ ?\%</^C1[K_PJ=)_^2J/^(?[_@KA_P!&CW7_ (5.D_\
MR51]4X8_N?\ @2_S#GQGG]QL_P#!1'_@NO\ M ?\%'_@)!^S_P#%/X->"]$T
MZW\0V^KQ7VA"[\\30QS1JO[V9UVE9FSQGIS7P[7V3_Q#_?\ !7#_ *-'NO\
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M'+O_ "E:\3_]BMHO_I(M? E???\ P<N_\I6O$_\ V*VB_P#I(M? E?K64_\
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M<22>69F8\L:\LT31-9\2ZS:>'/#NE7%]J%_<I;V-E:0F26XF=@J1HJY+,S$
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M;V4HU2RMHMTVJZ)DR2(H'+R0-NE5>ZO,!DE17\\M?VF$ C!%?A__ ,%P/^"
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M\/-)\,_A]>0ZAXHGGB_<ZC<J=]OIP[,78!I!VB5@<%TSYQ_P30_X)3_M$?\
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M/:Z/Y2[?_@C9_P %1[J98(OV(?'09CP9--5!^)9@!^->A_#K_@W?_P""L7Q
MN(TN?V=+;P] Y&;KQ%XHL(50>I2.9Y/R0FOZ<:*TGQ;CVO=A%??_ )B6"I=6
MS\0OV=O^#2GQS>W,&J?M6_M2:;I]N"#/HW@/3GN99!W NKH1K&??R7K],OV,
M_P#@E+^PU^PC%%?_  )^"UG_ &^D>V3Q=KQ^W:J_&"5GD'[D'NL(C4^E?1=%
M>1B\XS'&KEJU';LM%^&_S-H4*5/5(****\PV"BBB@#\P/^#A'_@E_P#M=_\
M!0GQO\,=;_9D\'Z9JEOX8TK4X-7;4-<@LS&\\MNT842L-V1&W3ICWK\Z?^(:
MG_@J]_T2;PU_X6ME_P#%U_2K17NX/B''X+#QHTU&R[IWWOW.:>%IU)N3N?(7
M_!$+]D'XW_L0?L+V?P*_:#T.ST[Q%#XHU&]>VL=1CNHQ#,R%#OC)7)P>.U?7
MM%%>1B*\\37E5GO)W9O&*A%170****Q*"BBB@#AOVA/V:O@3^U9\.;GX3_M"
M_##2O%6A77)L]3@RT+XP)89!AX9 "<21LK#/!K\DOVO_ /@T^EFO[KQ3^Q!\
M>8(H)&+Q>$O'JM^Z[[8[Z!6)'8*\6>.9#UK]IJ*[\%F>-R]_N9V7;=?=_D95
M*-.K\2/Y:/BO_P $+_\ @JE\(KJ6'5?V1=>UF&-B$N_"D\&J)*/55MI&D_-0
M?:O+;K_@G=^W[970LKS]B'XN13$X$;_#G4P2?IY%?UTT5[T.+L6E[U.+^]?Y
MG.\##HV?R@>!/^"0_P#P4X^(UTEKX>_8>^(D!D("OK?A^33$Y[[[SRE ]\U]
M:?LT_P#!J[^VK\2+VWU']H[X@^&?AQI3,#<6UO/_ &MJ0'<".$B <=S,<?W3
MTK^@NBL:_%>85%:FHQ_%_CI^ XX*DGKJ?,'[ _\ P2(_8P_X)Y6::K\(? C:
MKXM>#R[OQQXD*W.HN",,L1VA+9#W6)5R,;BV,U]/T45\[6KUL14<ZLG)OJSJ
MC&,%9(****R*"N;^+?P?^%WQZ^'VH_"KXR^!-,\2>'=6A\K4-)U:U66*4=C@
M_=8'!5UPRD @@@&NDHIQE*+33LP:3/QC_;3_ .#4BRU/4[OQC^PE\9H-.BE9
MI$\%^.&D:*+OMAOHU9]O8++&Q]9#7P#\6/\ @AM_P50^$-Y+;ZO^R%XAUF*-
MB$N_"<D.JI*/55MG=Q^*@^U?U-45]%AN)\RH1Y9VFO/?[U;\3EG@Z4G=:'\B
ML_\ P3P_;\M;D65S^Q%\7(YB2!$_PYU,,<>WD5V'P_\ ^"/G_!3WXEW26GA[
M]B#X@6QD. ^O:(VEH/<M>&( ?C7]75%=<N+\5;2E&_JS-8&'<_ C]EO_ (-4
MOVK?'VH6VK_M5?%30/ .DY#7&F:-)_:NIL.Z?(5MXR>F[S),==IZ']@/V'?^
M";O[)G_!/?P<_AK]G?X=I;ZA=Q*FL>*=487&J:ECG][.0,)GD1H$C!Y"YYKW
M>BO%QV<8_,%RU9>[V6B_X/SN=%.A2I;+4****\LV"BBB@#YU_;K_ ."6?['/
M_!0O1!#\>/ARL>OP0>5IWC/0F6UU6T4=%\[:1,@R<1RJZ#)( /-?D=^T_P#\
M&J?[6W@"^N=5_9=^*?AWX@:4&9K?3M5D_LG4P.R8<M;N1TW>:F>NT=!^_=%>
MK@LYS# +EIRO'L]5_P #Y&-2A2JZM:G\HGQ _P""/W_!3SX:74EKXB_8@^(-
MR8SAI-!T-M40^X:S\T$?C7(VW_!._P#;\O+DV5I^Q#\7))@<&-/ASJ98'Z>1
M7]=-%>S'B_%6UIQO\SG>!AW/Y8OA;_P0[_X*H_%FZB@T;]CSQ)I4<A&ZY\4O
M!I21CU874B/^ 4GVK[D_9(_X-//%EWJ%KXD_;8^/EG96:,'E\+^ E:::4==C
MWDZ*L?H0D3Y[,.M?MS17+B.*,RK1Y86AZ+7[W<N.#I1>NIYS^S%^R3^SO^QO
M\.(?A7^SA\+=-\,Z2A#7 M(RT][(!CS;B9B9)Y,<;G8D#@8  KT:BBOG9SG4
MDY3=V^K.I))604445(PHHHH ^)?^"@/_  09_8G_ &[;^\\?1Z++\/O'5V6>
M;Q5X4MT5+R4_QW=J<1W!SR7!21N\E?E1^T3_ ,&PW_!13X37L]U\(!X9^)>E
MH28)-&U5+&\*>KV]V44'V263ZU_1C17LX+/LRP45&,N:*Z2U_P"#^)A4PU*H
M[M:G\F'B[_@E;_P4E\#W36FO_L-?% E#AI=.\'75Y%_W\MT=/UK*T?\ X)Q?
M\%!=?F$&C_L/?%J=F.,K\/-2"CZL8<#KU)K^N2BO67%^*MK27WLP^HP[G\P?
MP;_X-^O^"JGQBNXD/[.#^%;20C=J'C+6+>Q2,'NT6]I_RC)K]"OV+O\ @U4^
M$7@+4;3QG^VQ\6W\:W4)#GPCX822STW</X9;EB)YU]E6'W)%?KE17!BN)<SQ
M,>6+4%_=W^]W_"QI#"48.[U,3X<_#;X??"'P7I_PY^%G@O3/#V@Z5 (=.TC1
M[)+>WMT'940 #GDGJ223DFMNBBO ;<G=G5L%%%%(#\7/^"U?_!%O]O;]M;]O
M76_CW\ ? .BZAX;OM"TVUM[F]\2VUK(9(;<)(#'(P8 ,.O>ODW_B&I_X*O?]
M$F\-?^%K9?\ Q=?TJT5]#A^)<PPU"-**C:*26CZ?,Y982E.3D[ZGCW_!/SX/
M>.?V??V)/A;\$?B98PVWB#PMX*L=-UBWM[E9DCN(H@KJKJ2K#(ZC@U[#117@
MU*DJM1SENVW]YTI65@HHHJ!A1110!^*O_!9__@BG^WU^VA^W[XF^/_P%\ :+
MJ'AK4]*TN"TN;WQ-;6TC/!9QQ2 QR,&&&4CWKY4_XAJ?^"KW_1)O#7_A:V7_
M ,77]*M%?0T.)<PP]"-**C:*26CZ?,Y982E*3;OJ>:?L9_#3Q9\&?V1_AC\(
M_'EI%;ZWX8\!:3I>KP0SK*D=S!:1Q2*KKPP#*1D<&O2Z**\"<W4FY/=ZG2E9
M6"N*_:"_9U^"W[4_PMU'X,?'WX?6'B3PYJ:8N+"^0Y1QG;+$ZD/%*N<K(A#+
MV-=K11&4H24HNS0-)JS/Q3_:E_X-,M4DUBZU[]C;]I"S6RE<M;^'/B!;.K0#
M^Z+VV1MX[#=""!U9J^8];_X-E?\ @JCI-VUM8>"O!VIH"0+BQ\90*C>X$PC;
M]*_I(HKWZ/$^:THV;4O5?Y6.:6$HR?8_FJ_XAJ?^"KW_ $2;PU_X6ME_\77V
M9_P0K_X(Z_MS_L*?ML7/QM_:*\"Z/IWA^3P1?Z:EQ8^([:Z<W$LULR+LC8G&
M(WYZ#'O7[$T4L3Q)F&*H2HS4;25G9/\ S'#"4H24E<****^?.D**** "BBB@
M HHHH **** $9@JEF/ &37SM\)/VA?V3/^"BVH:YX%NOA=_;*^$[A98T\4Z+
M"Z.CLR":$Y8IDI@@[6P1D'D#*^,7_!5W]GCX,_'.?X)Z[I&MW1TZ[6UUK6[.
M&,V]E,<;AM+!Y F?F*CC! #$8KC?^"@G[1UG^P?HVDK^R]\-_#>CZQ\09Y[W
M4]>@TB/:Z1;#NPH D=C-D%L@#=QELCZW*\AS!SA1E1E&M62=&7-RI6UDWU^'
MY^6J/R[B/C;(U1JXJ&+IU,)A&XXNGR>TG)R]VG&-[)?O-V[Q=MU9GRC^TA^U
MQ^U9\-_VH]=\+>"_&^K^$K'PKX@ET_P[X1T9C;Z?!:12%8$^RH!%*KH%;+*=
MV_(X(%?17_!3K]E[]J']I?1?A[\2_!'@^?4GM?#JQZWX:MIU62PO)0LCNJ.P
MW D[#CD>6,\'(U?V2?VC/&'[8/P#\?\ Q&U;X1>&]1^*W@;2I!X;\0QZ!"9K
MB>2WF>VV;E.V59(C\JD*<KP,FO%O^"9'QF_:PU_]KN+3/$?C/Q-JFBRQ7;^-
M8]>O)I8+5%B<K(_FDB%Q,(U&,'DKTSC[Z<L52F\30HTJ-; 1:FF[^TYH]&K.
MS6L6]7)V[W_$J,,NQ-.&7XS%8C%87.9Q=)Q7+['DJ-:J3E%N,O=FHI14(\RO
M[MNZ\+>'?V>?#O['UI^P=^U[^T%9^'O&$FK-?V]O"[70\.S.^Z&*61 85X9B
MZ,Z@"9N5X:OH3]@__@G_ .%?V-EU?Q'#X_D\3:OKL$<1U!;(6\,5LIWA$0.^
M=QP2Q;G"X YS\1_M'_\ !-K]K+Q#^T?X@U'P/X*?Q)I'B3Q!<W^F^(K>_A\A
MHIYFDS*S."C+NPV1SCY=V17Z@?!7P-J/PQ^#_A?X<ZOJHOKK0M M+"XNQG$K
MQ0JC,,\XRO&>V*^=XJQ<,/E<5A,;SK$MSJ07+9-V>EES15].5N[MKK<^\\-<
MJJX_B.<\SRGV,L!%4J%:7/S.*YHI.[Y*DN753C%))Z))Q.GHHHK\V/Z""BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0000""*YWXE_ ?X*Z_\  G6/A!JWPI\/2^%W\/SV?]@_V1"+5(!$P"+&%"H
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M#GQHT/X=^+;CQK8ZE:^%KF[M6\-PZBCHK3 2_:'A5OX"#""1P6''(:ON*@
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MX,NC#"XK$0G9J,)KR=O2V_D:U&YPBUU:/G7XM_%O]J__ (+W?M;:!^P9X_\
M@7H_P6TCX2^(4\0_$+1]9\1?:]5(3$+>4OEQF0^7,54(A0>>KL^"N?VQK\T/
M^"QW[-WQI_9Z_:B^&W_!73]C3X?:GKOBKPSJ,&D?$;PSH%C)/-K>F.#&LC1Q
M*S/^[9[=VP2H:!@!Y61^B_P\\;:;\2? >C?$+1K&^M;76]+@OK>UU.S>VN8%
MEC#B.:)P&BD7.&1@"K @]*SS*<*N&HRHI*G9Z+I+[5[MO71KR'23C.2EO^G0
M_'_X/?L_6G[5/_!2K_@H9^SW=0H\GBGP?/:6!D'$=X)8GMI.?[LZ1-_P&O$_
MV-/C1XC_ ."D7Q._8L_8&\26=T\'P3OM1U3Q]!<1MLDCTZ?=9Q2!NRVUM%;_
M %N2*^W?^";GPK^)WA;_ (+<_M:>/O$_PYU[3M"UJ./^Q]:O]'GAM+[_ $B(
M_N9G4)+P"?E)Z5[Y^R-_P2._9]_8Y_:_^(G[8OP\\0:O=ZU\06O=VE7R0BUT
MA+J[%U-';[$#;2ZJ!N)PJ@5ZM;,:&'YXRU?)!P\I.GRO\'^!C&E*=FN[OZ7N
M?,O_  1PX_X+ _MQ_P#8Y#_TXWU?=?[>/QTC_9H_8Q^)_P =1<B*X\-^"K^Y
MTUF. ;TPLELN?]J=XE_&OC+_ ()*_"SXG>#/^"KW[9WC'QA\.->TG2-=\6B3
M1-5U/1YX+;4$_M"];=!*ZA9AAE.4)&&![UU/_!QK_P +F\9?L*Z?^S[\#?AU
MK_B+5/B!XXT^QU"'0M)GNO(LH2UPSRF)6\M/.CMQEL#!/O7#B*<,3G-.#>C4
M+^G*KFD&X8=OU_,\%_X)*:A^PQH'_!%C7?V>?C#^US\*M \2_%JR\07'B#2]
M=\?Z;;W=G-=*]G;F6.28.C"*""7# $;J]A_X-B_CC)\2O^"<[_"G4[Y)+_X;
M^,;_ $GRUE#XM9B+R)@02"N^>= 1Q^[XKV7P#_P1(_X)E^&? NB^&_$'[('@
M_5;_ $_2;:VOM3NK1S+>31Q*CS.=_+.P+$^I-?//_!+OX">,?V%_^"OG[1/[
M-WAGX3:WI7PL\7:;;:[X0U.+2+C^RH7C9)4M8IROE@JE]<1[=V?]' /2MJ^(
MPF.P^)Y&^9M3ULMG9VU[/\"8QG3E"^VQ^G%%%%?-'6%%%% !1110 5YW^TS^
MT[\,OV4?AV/B-\3Y;MK>:\6TLK/3X1)/=3LK-L0,R@8568DD  >I ._\8?BM
MX6^!_P --7^*WC5;LZ7HML)KP6-N992I95&U<C/+#J0 ,DD $UQOQR^ GPA_
M;G^"&EZ3XQ_M*+3+]+?5]'OK4^1=6K/%E6PZL 2DA5E93U]0"/1R^AA_K%.K
MC8R]@Y6DX^6K2\[-7ZV/ SW&8]X+$87*9P^NJGS0C-Z:MI-KLVFD]KK70C^'
M_P 0/@'_ ,%!?V>KN>VTZXU'PSJ\C66K:7?;H)X9HV23RW,;95@?+<%6(P1S
MU%?)?B'_ (+):/\ "SQ^GPM^&GP/M+CP#X===*MWEU&1;J:VA_=!X\@JHVK\
MJMN) &6!)QY=X=_X*#Z]^Q5XMU'X%_LZ> M,D\':#XBN8[M_$(DEU#5Y4?RY
M9Y)49%B+",!55,*H7(8YSU/[4W[!'P4TCX-7O[=?A+Q;J]OX=UBQM-9A\%?8
M5+K)>R1[81<[_P!W&'F&<HQ ! ).*_3,#P]E>6XUT\SA)T*S_<1;;]Z5E[RB
M])M<MF]++5W1_/.<<><2<090L1P]5IQQN$C_ +9-1BKPA=WA*HGS4HRYW**U
M;:Y8M/74_:%_9+_9B_91\):7^W)X+EUG7]/U+5+*^\(>$+QD2S6>X4W,)FD4
M>88$5"WE\,=JJ7Y)KTC]ESXX_#G_ (*M>'M8^&'[3_P7TQ]0\,&.^L;K2IYX
MD\N0E"48/YD3 @ C>5<$<?+7-?L4?M4Z5^WO;:A^QI^T-\(M$;0XO#ZSZ+_8
MBSPK;1VQC1(_FD9E9592LBL/ND$'=7=?$W7OAA_P2CB\.>&_@'^SKJ&NGQUJ
MICU747U&1YG\HJ$A5]C[I#YK%(P%'#'DDD8XZ6,:>6XF,Y9A%WI3YTK0W^+F
MBD^523TNWUVMU9/3RJ'+G^7U*5/(IJV)I.E*3E5ORV=-PFVN>4'&TN6,=DM;
M_$NL_ME_'_X'_$[4/"_P7\13^#?#_A[7;F#3?"-G&#:Q(DS*5G1P3/(=OSO(
M2Q.<$# 'ZN_ +P'\,CX1T?XPZ#\&?#WAK7_$NA6U[JTFFZ+#!.))HDD>-G50
MQPQ[GMS6?XF_8M_98\>_$1/C!XL^".D7>OM(L\MU.CA99!@AY8@WER-ZEE)/
M?->I*JHH15  &  .E?-\2\1Y?F^'HQPE%TYI>^]/>VT;6LM;N\M;^K/T#P]X
M!SSA?'XJIFF*C7I2:]C&S:II7U2DK4W:T>6'NV25[)66BBBOC#];"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** # ZXHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BHX;NUN7DCM[F.1H7V2JC@E&P#@XZ'!!P?6N-T7XM:_JOQXUCX.7'
MPEUZTT[2]%AOH/&$\6-/O7<J#!&V.77<>^?D;(& 3K3HU*JDXKX5=ZI::+KO
MNM%J<U?%X?#N"F_CERJR;ULW;1.VB>KLO,[*6[M()8X)[F-'F8B%'< N0,D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYE=*RWV]ZA@L?G=.EQ5E#>,SG"RA3KPVIW2E%3M:#DU%*+Y)*+:<K6O?D?\
M@J;^SW\=/CUXK\'?$;]GWPQ<^*?!-UH*&Q@\-H)(XKB21I&N#&G:6-HOWF/X
M,$CC/UE^RY\&O$6F?LK^#/AQ^TGHECKFM:9I_P#IMOJ\,=X(&\QS%&2X8%HX
MF2/<,_=.">I[#X"?"BU^!GP:\-_".SU5[Y- TJ*T:\D3:9W RS[<G:"Q) R<
M# R<9KKJ_.\RXAKXG+J66P2]G1DW&:34FM;-ZZ73N^[M?8_>.'^!<'@,^Q&?
MUW+V^*IQ52DVI4XNT7)+35)QM&[=E=+1C+:VM[.W2TM+=(HHD"111H%5% P
M .  .U/HHKYK<_04DE9!1110,**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\1_#SQ_\-M,TMM-THZE87VC&7RQ$)DB,,OF,V9#Y@(8%00C_ "C%>:?M#_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  06,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Crescent Biopharma, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1686563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">300 Fifth Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">430-5595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CBIO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001253689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cbio-20251106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://crescentbiopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="cbio-20251106.htm">cbio-20251106.htm</File>
    <File>cbio-20251106.xsd</File>
    <File>cbio-20251106_lab.xml</File>
    <File>cbio-20251106_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cbio-20251106.htm": {
   "nsprefix": "cbio",
   "nsuri": "http://crescentbiopharma.com/20251106",
   "dts": {
    "inline": {
     "local": [
      "cbio-20251106.htm"
     ]
    },
    "schema": {
     "local": [
      "cbio-20251106.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cbio-20251106_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cbio-20251106_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://crescentbiopharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cbio-20251106.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cbio-20251106.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-25-049865-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-049865-xbrl.zip
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M:8@[-Y0<C#EAM,N!%T%;P4:#9Y>-36YVKG%'YB3_H8OW8E$67)93231-8L2
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M+FAT;>U=ZW/;1I+_?G_%G+V;R%4D3/ MR7&58L=9;SF.UW(N>_<E-02&Y$0
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M+%*E,\.^C*4.V;]RKF&45AC>R80G 70*#YD\@H=>#?1KGH3PV;:"(B6,8?^
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M12JX0#L/'9 @(-B@* !8H;:#N1<&W'SG;HDT(N?+6NI5%@_: C,# PL@8!X
MTHUE,*Z82VC,Y/"JA&D*--X\</Z=MOU0Z[G6.'-0E N1L4C *'4-L"4>:*#$
M?W)J&F;$ 6?U")Q\<M#JT$@V<0C?FB)\HI*ZB7D4L4# CRA'DVU!:8L2T_7:
MO;4D1AFR B=:1$3 TTRE)_66U^XOKAD,8"K8PK/7_OT+][/7-P/K^T.'=>>Q
M+_C0]EHMG/RG>;^2/!T'&U?@$ $LL"$ 0(Y:08(.8H,>A7-.7:B?3$/#7AF#
M9*1#YRJ0 K0!\>1]'.>)LH::5/0-23]%D;U3PX[0IWW!V@VPUF=)DL.H?A&"
MO 7H^R-U!M?^P?5 :8Q*]00\K- K1CRCWBNAP3E,N'Z(3@G 5TC^A;+HXYPM
M.\& 4 G!"":4CV+GCU-D#P]_][S=.X4_/O@,$0IT!6Z6>$9.4S)VT<F7.FD]
M>9Z6;.0+9UIYN$IE*@,&QY1P#WPS(X'<("4TZ&H8( !=\W*EI8)UV\62_CJ&
M;S66='O784ES)UA2..B102]>78$,I(J(O"1 L$+_523H" _!%"CP9.$G.*;$
M7V33%?"UGJE(6,%S2#\&ZP!>O0:>9& ?X670#LYPM1H<4YF@.89F<S!O"IHD
M!FL%KG!FY1#C]S2#H:@@R%,0H@G*B2@4L-!.L.DRX@-HTD:X#-<2[)K#K)(6
M"U*5:X73^"D?D$VE2P:<?"=5U1444M K,0!&"^^ QW>#Q^6:E@V<#/&45@5G
MHZ[D$GQ[.2H \:.X8F]U/F)'$(^]8#Q-"W86GLQOWKG'WBD5DM#2LV<AQ G2
MKAW,K N7X:9=[?UK;K5W&@H:YX_APB]$BFI8A_^ 62BW;(E=X;>(?4$J%70\
MYM&PB'R]&T5JUXNH8U$/46\1U%;MX;A.&M-7^  FD6>K7[G-ZC6@@B'Q6R)]
MWY(]"KS\]=6W^G.LIYH\$O4!&-"+.N':"8^N^,0\>TJ;8+L(EIND??1GJP96
MYI*LD(W@ZB%J-6C)G_F(+,X1[D.\V&!'9:OX_$7&, 9$IL\*#"%,?W[FK0<%
MT1 7=<J8NLH'6CZTK*"-'[N&I5(EC8K!)3!H[,=R(-&6IWP2*1ZZX!G?G(^[
MP9]P+@*(.$(B]@0@: -MB]74A05KKS3255">7:"KVH,5BW5[O>BUSA[NC0<_
M .LZTBI/PKJ;QY#^G=ZY0G,S9H7!H&VG93)^#\-;;B.^>^YW&Z<T2/1Q[UG_
M: A_\ULMKP5"&D5 HKVB#JHIN"&[H$JYWV<Y5&SZ[15YBO4V7'FL;$8 ,@UA
M,,S%N1AM9&,8WVB,4^@M"2OV7HL!?@37,%6$:8?BM%IZ])EB*W#'$9<3(\R^
MZK@;:#E.B/+ +NU$X9N-?=7WZ0Z\%AC_)]G8N WX P@L'^-#5.>?*5O +NWP
M2H!\*=C1SZ0G9_NOT&Z@^Z#0':]ST.>#/N],GS_BMITR>ZNJQ?AVYV,WVUYW
M+U6TA@E[NPD[O&9OKTC!P%]F VYHOQ[<3(E+BZ%-0:H=H.P&4/;PD.P<F8V9
M69G)..U8[BNFG1U"XVMAK5RP&_,0U^:T^DI[A-%D)T3SC[WN7E&HL$86WTRQ
MF5E)V*:]2*5!";B>%(\A,LY>8^*O7-J4)\.D,;FPVU\5'<+LG2#**0%@OD&8
MN=#1Q.7?UG'E O-#N=:\6)?%?=Y+Y7)O$]IBP)U8>'PH-*9,F$P%%QN@3;%Q
M@=OGF'-VSRNM9P.@#5O,K-^#I>'ELK(XU%(^+B656$A:$!_D,@+FLRNEX3<F
M<A''BT2T(K%_@)FFFZ?PVXWY>0$M4]&MB,&K$L0&^R[R:M=(?:PQEV" O]?:
M\/'8CQ/H!821TU3B/,HDYL+&*N21S*33%0$Z,(BD&>/"'&:O82E"24\N8[-8
MW2!<I@1P#JZM3, 5$O]>W,I0= VSXY"DU1T-+48R%@EU21F'0!EH?23FLPYQ
M%UO#5#22U?6-F<S([<S"_M75E1>X>0P*L?"@-WL;YSY44:2NJK#"< T>;W^0
MR84(WR?EP_:/?]LMDLHVR7WJ)<P9BQ/J'Y2Z0)Z>9\!P7&9<W/>XWY3Z-P!Y
MF.%MR@'9#7O0NI0RR;6(,,T*G'D2B6R,.3&Y1F,'#V5*4X[ #"MC/J',ITQF
MX.9BBDH;1F()$#D"3/NCV[0CYC(%8L$34FYK-H8BI!4=(X)<6^F/^)6I C_E
MB^<Z569J;:A9PX=8AX+99K8;T%L+*\XZN(P:3.@2['S:PP=99&>PSP*GQLX"
MDGG_^+A#:&$POV+5G K$J %N96Y_$>)$&4N[BE[#I1V;J*^9C--(DJDI7[<)
M"S:G;2&'QVX3VN7W&ANK5,"O 2"5&!)52+]QAE@@0[ET(YP2:"C788&-PQQ3
M BGS+*L@'>I6F<Q?$MC6OJ%EH2DX-E.-!8T%D_!$(H;20H2B4L(\L:2T>5'"
M%+4'1=+XDOWP*4=GVLX 62+*48;APC1R((X",S^4F*Y'<[;%$W,I*[.U'+8_
M.^P2!*L/W30WF39WBYXI(\:LV\M,6="T$L@F;SV<8J!=U *MRO5;S@FM$!S"
MN<0EFY8^4U&[@F\S^0+ 0NAQTXU^6]2WH,W5[;4 -VMUGEQQERH(WDYH+)1-
ME6I2LUA&/\NQ5B_&9>G(S*-%)6OE&OA!U8]8M5/][.!CID?K:E2O3*<P<Q5+
M["YG+A%(S5["ZB4! #CW<E'4-'LMC\+J!4RAB^=>M*!1O4* &,Y0 @S4#&&B
M62J J!@, V:N:?7G7,-F/#\@3.F<^8P/V,_(>P/@&7%=8#]A]-$LYB5B1 I?
MF#$0UDSHF&#UDFOI-EWMS?@%F5J)V3UR.+G&'ED[A!WP09D4;9NW(A8J8<A&
MH?%UN2W3]]$'QYMS':QA!RE!AKO2L:(:HVK K,6QQHM1ZJ$FX^_L4V5#UCX*
M@Y:ZHJ%B.,2<&1H*/ _RC#FUB5J]U/TT,@2;*_S*0X;@8H;@/1>Q&I-K"L5(
MS98*.@DUJD$9SA79XN"&&?<FU5</A$BJ-F0MW_121? J9TE.%1_H54ES 2B!
MY>L4#Y#G=H3Y;WC7YH+89+>)6F;%$*^UBEZ0^^=B1Y/':9$CPC,;%7!,O@?C
MF5=JXZG84U/\0%11.$_$=6VCU% ".719QFLIX# 4@67J00\F#M16S[Z@#TV8
M$&5VSM]TW!>F7MQTSAKT9N.B2=6?G7>"%[R4A68KP17N+[F8'P-=)S%\ .XO
M^#S0FBN1QW+=2X%6<XF;,7U:<VD0*5-T\VRRH3W[ ]WWTOE'HPCC<G0R1@62
M?!1;B3MU6J<),_;,@M([IX712_ G7!L$L3:':&%T:*.C2%BY0&<-.#)9,@MH
M0Y*04*D$)A7B6H04,]$@=# 645J,S08X6H4YD#[ 5</0UG/@</.$;B^PH[)F
M \V!8.9#E%I<M%C:VI*QAB+%/1PWV@LQ02DW*DE$M.3IPI<AV^[*%2LN'VD/
MTK/0#W P ["GZ/U0Y1*N.0$,@+(8G:>EEU")RUGE' PS,: /I'H(\<'8]DMA
MDXNS@?S1- B>XZV#BRJ52"N12)CS3\L[PYRT%R:JY<"6U2Q,.U8F*PZZ<.'<
MM(:\$H]C_S]]Q1K4$:WX%.>O5-PG9(Q+,85N[?%!2/EW&+W[C?J_7JSPP"U>
MW:!WCYV3"PB]"%8L:I6.E95ZN#P+, 6P@<V@#5+K19)B+RO8J<*HY3_,6($?
M!;[H/)"BC%SB^C<F!KMN"M Q5?!TSJSER;<1\Z/"M9G1\H6A8@(#X588; HT
MQRBW6KTTF- <K0Y8BV!K5%;:*2/(XP1VH&LGDVG%E(TL0GL@#+JJ25DQ58DG
MPJF%&0+&@06[IK/YMCWVORHOYH8V )H$3<Z3,!<S,'2MH5VZD&:M*7"%7T #
MN#1;+EJ%;NEA0J8G+FH0\<-?P&E0\I)GDLZMD!I+,X&VM&$AG/TD0O"<BHMP
M.V0Z)$O)2LYYZ?C3<EC&+TB2 5NP!(B.RLF=U7#L3JG4+++<S%.+I? *F!ZW
ML(;A<7)=-.+*)6?%J!P(+>1I=TQ%#% (FL*PYGK*87OZQ=0ZX9:0=3HR '"P
MW!;..-;,8:&5C6&F\+/Y[O'U14>K//U#J=*SUZU#('(7Y_5MLXYGC4V,%:?T
MV0.[D)-O%/HZZ(_#7[3?0PA<[G.@/OY:9HWC&T>$8RH'V0H-+H@3Y-A]7SI[
M1VCW"=V2%_3*;PD'8P\-;U(5M8QV&17<EBH%5DOC)GG$4R-.BC].P9D"V)^<
MR(2(02_=B-V-AM>P@IB!T&=AT;.[[=&MEUFX>*_=]8[]U;<;GK_RWG7-^EW/
M;Z]^];IFK[_7:MW!8#M>K]UZ2(/MKM7L2Q(&*Q @<R;ER0_/6B7&K,S?<'5M
M)PWFDX$J.KI)&\WT*[:RY$#0^:)_$NBMPLXW0:=-M6.8%/>+38K[:<6!>24:
MW((23X*:'W&3[T#,[1#S$YX^%-K :DI&_YC(V&9'[ZF0'NS="W!X;974 K7;
M,]3>&!' 3Q>+)&/T^WB6=E@%NU@/?/^T7' 3B9:_EJMG1='#C<30T<-9=$K"
M0J>"\D]P_+<3T#EJWZ:-1S?"VQJSS43W>'\D=U4!X;S\;D*(!EL"?D2%/9GT
MWVXUN^JLZ)#W?9E6LU%KM7LV8>PV,RP$>8.9;M/:'D1M_T6MW:HU.L<'43N(
MVMVC6JW=:^U.TN[7J=TCSV!U+?)*W[:Y&5F6:M1>R5ZGUFGU-Y2]:_A_5RBW
MKM_\Z/CC]VN-OG]@T/XRJ+-#]=EF4-?L/R#H_J(P-T:MORAQG=PYHGP[H'X8
M$MGLU/K]SLW\B?5HL&.?]BDRM>O7_';CP-1'Q=1FK=O:U+;?"T^?[CKW!SPK
MA'8,IF>HW28:>"RB>F2MRHM-O9S]P)XM>J>/AJ'6HAP8^F@82M9DS_CY9'>=
M?J5\1\P%C@4[<N') G.>HM/CUYJ]34/F@R.[WSP]:C<V< T.W-QO;E)Q0_-T
M'W5T2X')OFYPE:<5XI8$GIFCQ1@,!YXP@)?OQK8_HFV_S>:]MPIXU&S7NHW>
MGOER6_+-#T+[2(46 LI.^Y&N$!R$]I$*[1X'S<4HB@'3M^/L(N&[,MM6BB6)
M.1;GW#X9]C#$ZX;X5%S=:1U941U*M5^9FCLO=*PBH!\>E3-_3O-M=MX?'R0_
M$.#%,\ WQMT'Y!$<A&SWTSKJ>?WC@Y#M"3<>JY"UO.[FVVA[M+FRK_*RAH=P
M#BU#7V=KG!.^)1=B?6?ND>GDAA/?7W7U:\UNUVNW;[-?<=W4][S@XR"Y#U9R
M>[7^L>^U^@?)/4CN@Y+<;6THWH7P;F6Q[6[*NK>ZDG48XE87VQZ6*_T[?1!A
MG=.WEHB%K^*I?&,/RXTHSDE/<W*IDT5/_!;+<UNB[UXAG-^M==J-6J_G[_'I
M+'M%L6ZM"P1K-YH'@JU'L%ZK46L<SY+KD>\1+,#6AO'^S7#MSA85;F# W"EV
M\S9L?9]H;\6Y"<%,XS84VJ*;\'BI[-? Y3Y0^7[BFT5H?DDKE:\?P@FB=!@L
M'N)Y3H?Z3MB//*(SE,_' F#R+<_XPJF@-S_T$V.KAW+$9Z?G]7OM[1]$V?>.
M6\T[.#6S?<.#0Z\=[+'7[*QWQ.<W?)(- .7!'#1XHS,:'R,AWHK T<%_HJ<G
M+J?+F3$B.YR8>#B/$$_IYF9\.'MPY>SVULGS6ZU:LWO#<S4>T#;+0=9V/ZU6
MN];K=@]'PNVH;)=?;ZX?W1E6G5JCT3Z<,;:W_.EW=G@"W!,_8VRYZ[[!IO73
MJ ?:;-Y[JVE^JP].W@V/_=V/2K;M9=D<)/<!26ZK4^OZ-SP:_4'4[#_ 99\/
MTGZM:_$=E>>5_<+OV4]_Y?C-H4=OQ5 &,EM].,QA>>@)+0]59.:P2O3P(O>F
M7^LV;WB\T0/R$@ZBMOMIM7NUQO%AD>C^"3]KQH4SXZ$SX^[LGM5)24]G7<GW
M,<OO<'K]_G+HR/=K[=YN:F2?^,)2-!<<F&M1Y88AG4N1F?.XGWB,?RNB[*TJ
M;V/IZC:4V7./]: 03TTAMK BM@M]V#!QU-&54C<WRK_\]EN.FKTFD#M51N)A
M^"=:1/056=.\2LS\J[SE.FE,7^$#(%&>K7[E%KFO9VFF#(@(3^J;BPGEO+87
MYK^2-M6?X[)D,.4C41]HP2_J? B#/^'1%9^8V2G&0'[7;;_G=;LPM$VH(>,1
MXU'VPS,90V]_-+CW9SH"L-3!PJ49WG4;Z=<;I<MV^^G79[,S7D.>UF&8ECPB
MAIDE'/MVGK+[3E>(J$02"//=\T[_= 4'MS^:!0GR.VAY/0;__@VB/F)G-28R
M8)7'BD%M>234THD$#U(&:XSM ^9P9W<TEFM[]B@1%OAS?,K:C<Z1WVCW_1?$
MKW[KN-YO'WL[YEN3^/9_8^3;ESWCFSP/) KXSCC7MIQK]H]:EFF^[_>:S54\
M6VY);F.;[@%+"/_?P!,\R'8,)"U,KC^+)^RSD%$TV?% WHRE&+(W*H[S!.P$
M?0L.^W4(H:C0.QX:CR>>)AI]][S;/@VT,&@E!U*E$$#'W M4S'8\1G [Z^UN
MI][H]+M/W+OJW,R[>CE0X01^C;,X>OW_4$L! A0#%     @ USMF6YY;4$=;
M#P  +FT  !$              ( !     &-B:6\M,C R-3$Q,#8N:'1M4$L!
M A0#%     @ USMF6\OB?XMG @  " <  !$              ( !B@\  &-B
M:6\M,C R-3$Q,#8N>'-D4$L! A0#%     @ USMF6Q]I&Q8;"@  ?54  !4
M             ( !(!(  &-B:6\M,C R-3$Q,#9?;&%B+GAM;%!+ 0(4 Q0
M   ( -<[9EL<:7?\L 8  .@P   5              "  6X<  !C8FEO+3(P
M,C4Q,3 V7W!R92YX;6Q02P$"% ,4    " #7.V9;&7B]?=T8  "DV@  %P
M            @ %1(P  <')E<W-R96QE87-E+7$S,C R-2YH=&U02P4&
/  4 !0!) 0  8SP

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>cbio-20251106_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cbio-20251106.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2025-11-06</startDate>
            <endDate>2025-11-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001253689</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-11-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Crescent Biopharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36177</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">06-1686563</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">300 Fifth Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">430-5595</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Ordinary Shares, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">CBIO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
